Search

Johnson & Johnson Reports Q2 2021 Results - PRNewswire

sisilihya.blogspot.com

NEW BRUNSWICK, N.J., July 21, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. "Our second-quarter results showcase Johnson & Johnson's diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses," said Alex Gorsky, Chairman and Chief Executive Officer. "I'm so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These accomplishments exemplify our commitment to advancing transformational innovations that improve the health of people and communities everywhere while continuing to deliver long-term value to all of our stakeholders."

OVERALL FINANCIAL RESULTS


Q2



($ in Millions, except EPS)

2021

2020

%  Change

Reported Sales

$       23,312

$       18,336

27.1%

Net Earnings

6,278

3,626

73.1

EPS (diluted)

$           2.35

$           1.36

72.8%





Q2



Non-GAAP*($ in Millions, except EPS)

2021

2020

%  Change

Operational Sales1,2



23.0%

Adjusted Operational Sales1,3



23.8

Adjusted Net Earnings1,4

6,625

4,446

49.0

Adjusted EPS (diluted)1,4

$           2.48

$           1.67

48.5%



1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

4

Excludes intangible amortization expense and special items

REGIONAL SALES RESULTS


Q2


%  Change

($ in Millions)

2021

2020

Reported

Operational1,2

Currency

Adjusted
Operational
1,3

U.S.

$      11,919

$        9,539

24.9%

24.9

-

25.1

International

11,393

8,797

29.5

20.9

8.6

22.4

Worldwide

$      23,312

$      18,336

27.1%

23.0

4.1

23.8



1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency


Note: values may have been rounded

SEGMENT SALES RESULTS


Q2


%  Change

($ in Millions)

2021

2020

Reported

Operational1,2

Currency

Adjusted
Operational
1,3

Consumer Health

$        3,735

$        3,296

13.3%

9.2

4.1

10.0

Pharmaceutical

12,599

10,752

17.2

13.6

3.6

14.1

Medical Devices

6,978

4,288

62.7

57.2

5.5

58.7

Worldwide

$      23,312

$      18,336

27.1%

23.0

4.1

23.8



1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency


Note: values may have been rounded

Second Quarter 2021 SEGMENT COMMENTARY: 

Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased 10.0%* inclusive of the market recovery from COVID-19 impacts, primarily in skin health/beauty.  Sales growth was driven by skin health/beauty products including NEUTROGENA, AVEENO, and OGX; over-the-counter products including ZYRTEC in upper respiratory products, international analgesics, and digestive health products; and BAND-AID® Brand Adhesive Bandages in wound care products. 

Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 14.1%* driven by STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, and INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases.

Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 58.7%*, primarily driven by the benefit of market recovery from COVID-19 impacts and the associated deferral of medical procedures in the prior year across all of our businesses including Surgery, Orthopaedics, Vision and Interventional Solutions.

NOTABLE NEW ANNOUCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the company's website at news releases.

Regulatory
Decisions

TECNIS SYNERGY and TECNIS SYNERGY TORIC II IOLS a Next Generation Treatment for Cataract Patients Received Regulatory Approval and Launched in the U.S. and Canada

(press release)

(press release)

RYBREVANT (amivantamab-vmjw) Receives U.S. FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

(press release)

PONVORY (ponesimod) receives European Commission approval for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features

(press release)

DARZALEX (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma

(press release)

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) Receives U.S. FDA Approval for Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse1

(press release)

Regulatory
Submissions

Janssen granted Breakthrough Therapy Designation from the U.S. FDA for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

(press release)

Janssen Submits Marketing Authorisation Application to the European Medicines Agency for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

(press release)

Janssen Submits New Drug Application to U.S. FDA for XARELTO (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

(press release)

Other

Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa

(press release)

Janssen Discontinues Collaboration and License Agreement with argenx for Cusatuzumab

(press release)

ETHICON expands Advanced Bipolar Energy Portfolio with Launch of ENSEAL X1 Curved Jaw Tissue Sealer

(press release)

Johnson & Johnson Announces Positive New Data for the Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

(press release)

Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA and AVEENO Aerosol Sunscreen Products Due to the Presence of Benzene1

(press release)

1Subsequent to the quarter

FULL-YEAR 2021 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)

April 2021 

July 2021 (Base Business)

July 2021 (incl. COVID Vx)

Adjusted Operational Sales1,2

Change vs. Prior Year

8.7% - 9.9%

9.5% - 10.5%

12.5% - 13.5%

Operational Sales2

Change vs. Prior Year

$89.3B - $90.3B

8.2% – 9.4%

$90.0B - $90.8B

9.0% – 10.0%

$92.5B - $93.3B

12.0% – 13.0%

Estimated Reported Sales3

Change vs. Prior Year

$90.6B - $91.6B

9.7% – 10.9%

$91.3B - $92.1B

10.5% – 11.5%

$93.8B - $94.6B

13.5% – 14.5%





Adjusted Operational EPS
(Diluted)2,4

Change vs. Prior Year

$9.30 - $9.45

15.8% - 17.7%


$9.50 - $9.60

18.4% - 19.6%

Adjusted EPS (Diluted)3,4

Change vs. Prior Year

$9.42 - $9.57

17.3% - 19.2%


$9.60 - $9.70

19.6% - 20.8%



1

Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

2

Non-GAAP financial measure; excludes the impact of translational currency

3

Calculated using Euro Average Rate: April 2021 = $1.19 and July 2021 = $1.19 (Illustrative purposes only)

4

Non-GAAP financial measure; excludes intangible amortization expense and special items


Note: % may have been rounded

Other modeling considerations will be provided on the webcast.

WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at events-and-presentations

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at quarterly-results.

Copies of the financial schedules accompanying this earnings release are available on the company's website at quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investors section of the company's website at quarterly-results.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," in the Company's most recently filed Quarterly Report on Form 10-Q and the Company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries













Supplementary Sales Data

































(Unaudited; Dollars in Millions)

SECOND QUARTER


SIX MONTHS






 Percent Change






Percent Change


2021


2020


Total


Operations


Currency


2021


2020


Total


Operations


Currency

Sales to customers by




















segment of business








































Consumer Health




















    U.S.

$   1,751


1,557


12.4

%

12.4


-


$   3,362


3,297


2.0

%

2.0


-

    International

1,984


1,739


14.1


6.3


7.8


3,916


3,624


8.1


3.3


4.8


3,735


3,296


13.3


9.2


4.1


7,278


6,921


5.2


2.7


2.5





















Pharmaceutical




















    U.S.

6,869


6,120


12.2


12.2


-


13,315


12,181


9.3


9.3


-

    International

5,730


4,632


23.7


15.4


8.3


11,483


9,705


18.3


11.4


6.9


12,599


10,752


17.2


13.6


3.6


24,798


21,886


13.3


10.3


3.0





















Medical Devices




















    U.S.

3,299


1,862


77.2


77.2


-


6,353


4,760


33.5


33.5


-

    International

3,679


2,426


51.6


41.9


9.7


7,204


5,460


31.9


24.5


7.4


6,978


4,288


62.7


57.2


5.5


13,557


10,220


32.7


28.7


4.0





















U.S.

11,919


9,539


24.9


24.9


-


23,030


20,238


13.8


13.8


-

International

11,393


8,797


29.5


20.9


8.6


22,603


18,789


20.3


13.7


6.6

Worldwide

$ 23,312


18,336


27.1

%

23.0


4.1


$ 45,633


39,027


16.9

%

13.7


3.2





















Note:Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. 

Johnson & Johnson and Subsidiaries




















Supplementary Sales Data








































(Unaudited; Dollars in Millions)

SECOND QUARTER


SIX MONTHS






Percent Change






Percent Change


2021


2020


Total


Operations


Currency


2021


2020


Total


Operations


Currency

Sales to customers by




















geographic area








































U.S.

$ 11,919


9,539


24.9

%

24.9


-


$ 23,030


20,238


13.8

%

13.8


-





















Europe

5,668


4,063


39.5


28.6


10.9


11,082


8,890


24.7


15.6


9.1

Western Hemisphere excluding U.S.

1,367


1,133


20.6


12.7


7.9


2,791


2,635


5.9


5.4


0.5

Asia-Pacific, Africa

4,358


3,601


21.0


14.8


6.2


8,730


7,264


20.2


14.2


6.0

International

11,393


8,797


29.5


20.9


8.6


22,603


18,789


20.3


13.7


6.6





















Worldwide

$ 23,312


18,336


27.1

%

23.0


4.1


$ 45,633


39,027


16.9

%

13.7


3.2





















Note:Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

 

Johnson & Johnson and Subsidiaries










Condensed Consolidated Statement of Earnings 




















(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER












2021


2020


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$ 23,312


100.0


$ 18,336


100.0


27.1

Cost of products sold

7,587


32.5


6,579


35.9


15.3

Gross Profit

15,725


67.5


11,757


64.1


33.8

Selling, marketing and administrative expenses

6,073


26.1


4,993


27.2


21.6

Research and development expense

3,394


14.6


2,707


14.8


25.4

In-process research and development

0


0.0


6


0.0



Interest (income) expense, net

28


0.1


26


0.2



Other (income) expense, net

(488)


(2.1)


24


0.1



Restructuring

56


0.2


61


0.3



Earnings before provision for taxes on income

6,662


28.6


3,940


21.5


69.1

Provision for taxes on income

384


1.7


314


1.7


22.3

Net earnings

$   6,278


26.9


$   3,626


19.8


73.1











Net earnings per share (Diluted)

$     2.35




$     1.36




72.8











Average shares outstanding (Diluted)

2,671.6




2,665.5















Effective tax rate

5.8

%



8.0

%














Adjusted earnings before provision for taxes and net earnings (1)










Earnings before provision for taxes on income

$   7,776


33.4


$   5,337


29.1


45.7

Net earnings

$   6,625


28.4


$   4,446


24.2


49.0

Net earnings per share (Diluted)

$     2.48




$     1.67




48.5

Effective tax rate

14.8

%



16.7

%














(1)See Reconciliation of Non-GAAP Financial Measures.










Johnson & Johnson and Subsidiaries










Condensed Consolidated Statement of Earnings 




















(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS












2021


2020


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$ 45,633


100.0


$ 39,027


100.0


16.9

Cost of products sold

14,650


32.1


13,641


35.0


7.4

Gross Profit

30,983


67.9


25,386


65.0


22.0

Selling, marketing and administrative expenses

11,505


25.2


10,196


26.1


12.8

Research and development expense

6,572


14.4


5,287


13.5


24.3

In-process research and development

0


0.0


6


0.0



Interest (income) expense, net

76


0.2


(16)


0.0



Other (income) expense, net

(1,370)


(3.0)


(655)


(1.7)



Restructuring

109


0.2


119


0.3



Earnings before provision for taxes on income

14,091


30.9


10,449


26.8


34.9

Provision for taxes on income

1,616


3.6


1,027


2.7


57.4

Net earnings

$ 12,475


27.3


$   9,422


24.1


32.4











Net earnings per share (Diluted)

$     4.67




$     3.53




32.3











Average shares outstanding (Diluted)

2,674.0




2,671.0















Effective tax rate

11.5

%



9.8

%














Adjusted earnings before provision for taxes and net earnings (1)










Earnings before provision for taxes on income

$ 16,067


35.2


$ 12,581


32.2


27.7

Net earnings

$ 13,549


29.7


$ 10,600


27.2


27.8

Net earnings per share (Diluted)

$     5.07




$     3.97




27.7

Effective tax rate

15.7

%



15.7

%














(1)See Reconciliation of Non-GAAP Financial Measures.










Johnson & Johnson and Subsidiaries








Reconciliation of Non-GAAP Financial Measures 



















Second Quarter


Six Months Ended


(Dollars in Millions Except Per Share Data)

2021


2020


2021


2020


Net Earnings, after tax- as reported

$6,278


$3,626


$12,475


$9,422











Pre-tax Adjustments 









Intangible Asset Amortization expense

1,202


1,127


2,417


2,245


Litigation related

(23)


613


(23)


733


IPR&D

-


6


-


6


Restructuring related

108


115


212


233


Acquisition, integration and divestiture related ¹

14


29


(524)


(933)


Unrealized (gains)/losses on securities 

(243)


(533)


(208)


(206)


Medical Device Regulation

56


37


102


51


Other

-


3


-


3











Tax Adjustments









Tax impact on special item adjustments 2

(135)


(253)


(248)


(520)


Tax legislation and other tax related

(632)


(324)


(654)


(434)


Adjusted Net Earnings, after tax

$6,625


$4,446


$13,549


$10,600


Average shares outstanding (Diluted)

2,671.6


2,665.5


2,674.0


2,671.0


Adjusted net earnings per share (Diluted)

$2.48


$1.67


$5.07


$3.97


Operational adjusted net earnings per share (Diluted)

$2.42




$4.91













Notes:








1

Acquisition, integration and divestiture related for the six months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.  The six months of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition. 










2

The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.


Johnson & Johnson and Subsidiaries







Reconciliation of Non-GAAP Financial Measure
















Adjusted Operational Sales Growth

 SECOND QUARTER 2021 ACTUAL vs. 2020 ACTUAL 


 Segments 












Consumer Health


 Pharmaceutical 


 Medical Devices 


 Total 










 WW As Reported 


13.3%


17.2%


62.7%


27.1%

 U.S. 


12.4%


12.2%


77.2%


24.9%

 International 


14.1%


23.7%


51.6%


29.5%










 WW Currency 


4.1


3.6


5.5


4.1

 U.S. 


-


-


-


-

 International 


7.8


8.3


9.7


8.6










 WW Operational 


9.2%


13.6%


57.2%


23.0%

 U.S. 


12.4%


12.2%


77.2%


24.9%

 International 


6.3%


15.4%


41.9%


20.9%










General Surgery









Advanced Sterilization Products






1.2


0.2

 U.S. 






0.0


0.0

 International 






1.9


0.4










All Other Acquisitions and Divestitures


0.8


0.6


0.3


0.6

 U.S. 


0.6


(0.1)


0.7


0.1

 International 


1.1


1.5


0.0


1.0










WW Adjusted Operational


10.0%


14.1%


58.7%


23.8%

 U.S. 


13.0%


12.1%


77.9%


25.1%

 International 


7.4%


16.8%


43.8%


22.4%










Note: Percentages are based on actual, non-rounded figures and may not sum



Johnson & Johnson and Subsidiaries







Reconciliation of Non-GAAP Financial Measure
















Adjusted Operational Sales Growth

 SIX MONTHS 2021 ACTUAL vs. 2020 ACTUAL 


 Segments 












Consumer Health


 Pharmaceutical 


 Medical Devices 


 Total 










 WW As Reported 


5.2%


13.3%


32.7%


16.9%

 U.S. 


2.0%


9.3%


33.5%


13.8%

 International 


8.1%


18.3%


31.9%


20.3%










 WW Currency 


2.5


3.0


4.0


3.2

 U.S. 


-


-


-


-

 International 


4.8


6.9


7.4


6.6










 WW Operational 


2.7%


10.3%


28.7%


13.7%

 U.S. 


2.0%


9.3%


33.5%


13.8%

 International 


3.3%


11.4%


24.5%


13.7%










General Surgery









Advanced Sterilization Products






0.8


0.2

 U.S. 






0.0


0.0

 International 






1.5


0.4










All Other Acquisitions and Divestitures


0.6


0.5


0.2


0.4

 U.S. 


0.5


(0.1)


0.5


0.1

 International 


0.7


1.2


0.0


0.8










WW Adjusted Operational


3.3%


10.7%


29.7%


14.4%

 U.S. 


2.5%


9.2%


33.9%


13.9%

 International 


4.0%


12.6%


26.0%


14.8%










Note: Percentages are based on actual, non-rounded figures and may not sum






REPORTED SALES vs. PRIOR PERIOD ($MM)






REPORTED SALES vs. PRIOR PERIOD ($MM)



SECOND QUARTER





SIX MONTHS







% Change








% Change




2021


2020

Reported

Operational (1)

Currency





2021


2020

Reported

Operational (1)

Currency


CONSUMER HEALTH SEGMENT (2) 



















OTC



















US


$             675


627

7.7%

7.7%

-





$          1,274


1,316

-3.2%

-3.2%

-


Intl


633


522

21.2%

10.4%

10.8%





1,208


1,181

2.3%

-4.7%

7.0%


WW


1,307


1,149

13.8%

8.9%

4.9%





2,482


2,497

-0.6%

-3.9%

3.3%


SKIN HEALTH / BEAUTY



















US


659


536

23.0%

23.0%

-





1,293


1,195

8.2%

8.2%

-


Intl


511


471

8.4%

1.4%

7.0%





1,040


929

12.0%

6.8%

5.2%


WW


1,170


1,007

16.2%

12.9%

3.3%





2,333


2,124

9.8%

7.6%

2.2%


ORAL CARE



















US


165


170

-3.1%

-3.1%

-





328


346

-5.2%

-5.2%

-


Intl


260


227

14.6%

6.7%

7.9%





514


446

15.3%

10.2%

5.1%


WW


426


397

7.0%

2.5%

4.5%





843


792

6.3%

3.5%

2.8%


BABY CARE



















US


97


96

0.8%

0.8%

-





193


188

2.4%

2.4%

-


Intl


290


260

11.5%

6.6%

4.9%





583


529

10.2%

9.0%

1.2%


WW


387


356

8.6%

5.0%

3.6%





776


717

8.1%

7.3%

0.8%


WOMEN'S HEALTH



















US


3


3

-3.1%

-3.1%

-





6


7

-16.0%

-16.0%

-


Intl


227


199

14.2%

9.2%

5.0%





446


427

4.5%

3.1%

1.4%


WW


230


202

13.9%

9.0%

4.9%





452


434

4.2%

2.8%

1.4%


WOUND CARE / OTHER



















US


153


126

20.9%

20.9%

-





268


245

9.3%

9.3%

-


Intl


64


59

7.3%

-2.8%

10.1%





125


111

12.1%

5.2%

6.9%


WW


216


185

16.6%

13.4%

3.2%





393


356

10.2%

8.0%

2.2%





















TOTAL CONSUMER HEALTH



















US


1,751


1,557

12.4%

12.4%

-





3,362


3,297

2.0%

2.0%

-


Intl


1,984


1,739

14.1%

6.3%

7.8%





3,916


3,624

8.1%

3.3%

4.8%


WW


$          3,735


3,296

13.3%

9.2%

4.1%





$          7,278


6,921

5.2%

2.7%

2.5%








































See footnotes at end of schedule




















REPORTED SALES vs. PRIOR PERIOD ($MM)





REPORTED SALES vs. PRIOR PERIOD ($MM)



SECOND QUARTER




SIX MONTHS







% Change








% Change


PHARMACEUTICAL SEGMENT (2,3)


2021


2020

Reported

Operational (1)

Currency





2021


2020

Reported

Operational (1)

Currency





















IMMUNOLOGY



















US


$          2,748


2,362

16.4%

16.4%

-





$          5,161


4,772

8.2%

8.2%

-


Intl


1,483


1,161

27.7%

18.2%

9.5%





2,984


2,389

24.9%

17.0%

7.9%


WW


4,231


3,523

20.1%

17.0%

3.1%





8,145


7,161

13.7%

11.1%

2.6%


REMICADE



















US 


540


593

-9.1%

-9.1%

-





1,029


1,218

-15.6%

-15.6%

-


US Exports (4)


93


133

-30.0%

-30.0%

-





150


243

-38.2%

-38.2%

-


Intl


255


208

22.4%

11.1%

11.3%





487


464

4.9%

-1.7%

6.6%


WW


888


935

-5.1%

-7.6%

2.5%





1,665


1,925

-13.5%

-15.1%

1.6%


SIMPONI / SIMPONI ARIA



















US


290


256

12.8%

12.8%

-





545


528

3.2%

3.2%

-


Intl


294


289

1.7%

-3.8%

5.5%





601


547

9.8%

4.5%

5.3%


WW


584


546

6.9%

4.0%

2.9%





1,146


1,075

6.6%

3.8%

2.8%


STELARA



















US


1,496


1,138

31.4%

31.4%

-





2,827


2,355

20.0%

20.0%

-


Intl


778


558

39.2%

28.6%

10.6%





1,595


1,161

37.3%

28.1%

9.2%


WW


2,274


1,697

34.0%

30.5%

3.5%





4,422


3,516

25.8%

22.7%

3.1%


TREMFYA



















US


325


241

35.0%

35.0%

-





599


428

40.0%

40.0%

-


Intl


155


101

52.3%

41.1%

11.2%





298


210

41.8%

31.8%

10.0%


WW


479


342

40.2%

36.8%

3.4%





897


638

40.6%

37.3%

3.3%


OTHER IMMUNOLOGY



















US


5


-

*

*

-





12


-

*

*

-


Intl


1


3

-61.3%

-67.9%

6.6%





3


6

-51.2%

-53.9%

2.7%


WW


7


3

*

*

*





15


6

*

*

*


INFECTIOUS DISEASES



















US


444


416

6.8%

6.8%

-





956


852

12.2%

12.2%

-


Intl


585


463

26.3%

18.2%

8.1%





1,079


946

14.1%

7.8%

6.3%


WW


1,028


878

17.1%

12.8%

4.3%





2,035


1,798

13.2%

9.9%

3.3%


COVID-19 VACCINE



















US


51


-

*

*

-





151


-

*

*

-


Intl


113


-

*

*

-





113


-

*

*

-


WW


164


-

*

*

-





264


-

*

*

-


EDURANT / rilpivirine



















US


9


10

-9.3%

-9.3%

-





19


22

-10.9%

-10.9%

-


Intl


253


246

2.8%

-4.0%

6.8%





486


458

6.0%

-1.7%

7.7%


WW


262


256

2.3%

-4.2%

6.5%





505


480

5.2%

-2.1%

7.3%


PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA



















US


368


379

-3.2%

-3.2%

-





748


775

-3.5%

-3.5%

-


Intl


137


130

5.5%

-5.9%

11.4%





303


314

-3.5%

-8.5%

5.0%


WW


505


510

-1.0%

-3.9%

2.9%





1,051


1,089

-3.5%

-5.0%

1.5%


OTHER INFECTIOUS DISEASES



















US


16


25

-36.2%

-36.2%

-





37


54

-31.3%

-31.3%

-


Intl


81


87

-6.2%

-13.4%

7.2%





177


174

1.8%

-3.0%

4.8%


WW


98


113

-13.0%

-18.5%

5.5%





215


229

-6.1%

-9.7%

3.6%
























REPORTED SALES vs. PRIOR PERIOD ($MM)






REPORTED SALES vs. PRIOR PERIOD ($MM)



SECOND QUARTER





SIX MONTHS







% Change








% Change




2021


2020

Reported

Operational (1)

Currency





2021


2020

Reported

Operational (1)

Currency


NEUROSCIENCE



















US


842


778

8.0%

8.0%

-





1,613


1,526

5.6%

5.6%

-


Intl


967


809

19.6%

13.1%

6.5%





1,916


1,719

11.5%

6.3%

5.2%


WW


1,808


1,587

13.9%

10.6%

3.3%





3,529


3,245

8.7%

6.0%

2.7%


CONCERTA / Methylphenidate



















US


35


55

-36.0%

-36.0%

-





82


107

-23.1%

-23.1%

-


Intl


127


94

33.7%

25.6%

8.1%





250


212

17.5%

11.1%

6.4%


WW


161


149

8.1%

3.0%

5.1%





332


320

3.9%

-0.3%

4.2%


INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA



















US


645


576

11.9%

11.9%

-





1,234


1,120

10.2%

10.2%

-


Intl


380


303

25.1%

15.9%

9.2%





756


642

17.7%

9.9%

7.8%


WW


1,024


879

16.4%

13.3%

3.1%





1,989


1,762

12.9%

10.1%

2.8%


RISPERDAL CONSTA



















US


72


74

-3.0%

-3.0%

-





139


150

-7.5%

-7.5%

-


Intl


84


79

6.4%

0.2%

6.2%





173


173

0.4%

-4.6%

5.0%


WW


155


153

1.9%

-1.3%

3.2%





312


323

-3.3%

-6.0%

2.7%


OTHER NEUROSCIENCE



















US


91


75

20.9%

20.9%

-





158


150

5.6%

5.6%

-


Intl


377


331

13.8%

10.0%

3.8%





738


691

6.7%

4.3%

2.4%


WW


468


406

15.1%

12.0%

3.1%





896


841

6.5%

4.5%

2.0%


ONCOLOGY



















US


1,462


1,181

23.7%

23.7%

-





2,839


2,356

20.5%

20.5%

-


Intl


2,073


1,609

28.8%

19.8%

9.0%





4,266


3,448

23.7%

16.2%

7.5%


WW


3,535


2,791

26.7%

21.5%

5.2%





7,105


5,804

22.4%

17.9%

4.5%


DARZALEX



















US


770


492

56.7%

56.7%

-





1,461


955

53.1%

53.1%

-


Intl


663


409

62.1%

50.3%

11.8%





1,337


883

51.4%

42.3%

9.1%


WW


1,433


901

59.2%

53.8%

5.4%





2,798


1,838

52.2%

47.9%

4.3%


ERLEADA



















US


193


136

41.5%

41.5%

-





364


255

42.7%

42.7%

-


Intl


109


33

*

*

*





199


57

*

*

*


WW


302


170

77.6%

73.7%

3.9%





563


313

80.0%

76.4%

3.6%


IMBRUVICA



















US


454


447

1.7%

1.7%

-





898


879

2.2%

2.2%

-


Intl


662


502

31.9%

22.1%

9.8%





1,342


1,101

21.9%

14.2%

7.7%


WW


1,116


949

17.7%

12.5%

5.2%





2,241


1,980

13.2%

8.9%

4.3%


ZYTIGA / abiraterone acetate



















US


21


87

-75.3%

-75.3%

-





71


226

-68.5%

-68.5%

-


Intl


542


480

12.8%

5.4%

7.4%





1,130


1,032

9.5%

2.5%

7.0%


WW


563


568

-0.8%

-7.1%

6.3%





1,201


1,258

-4.5%

-10.3%

5.8%


OTHER ONCOLOGY



















US


23


20

18.8%

18.8%

-





44


42

6.3%

6.3%

-


Intl


97


185

-47.2%

-49.6%

2.4%





258


375

-31.0%

-34.3%

3.3%


WW


120


204

-40.9%

-43.0%

2.1%





302


416

-27.3%

-30.2%

2.9%























REPORTED SALES vs. PRIOR PERIOD ($MM)





REPORTED SALES vs. PRIOR PERIOD ($MM)




SECOND QUARTER




SIX MONTHS







% Change








% Change




2021


2020

Reported

Operational (1)

Currency





2021


2020

Reported

Operational (1)

Currency


PULMONARY HYPERTENSION



















US


595


545

9.0%

9.0%

-





1,168


1,031

13.2%

13.2%

-


Intl


275


243

13.5%

7.9%

5.6%





563


503

12.1%

6.7%

5.4%


WW


870


789

10.4%

8.7%

1.7%





1,731


1,534

12.9%

11.1%

1.8%


OPSUMIT



















US


290


256

13.6%

13.6%

-





562


485

15.9%

15.9%

-


Intl


172


150

14.9%

9.0%

5.9%





351


310

13.1%

7.6%

5.5%


WW


463


406

14.1%

11.9%

2.2%





913


795

14.8%

12.7%

2.1%


UPTRAVI



















US


268


254

6.0%

6.0%

-





527


466

13.3%

13.3%

-


Intl


45


28

54.9%

42.9%

12.0%





91


66

36.8%

27.4%

9.4%


WW


313


282

11.0%

9.8%

1.2%





618


532

16.2%

15.0%

1.2%


OTHER PULMONARY HYPERTENSION



















US


36


37

-2.4%

-2.4%

-





78


81

-3.0%

-3.0%

-


Intl


59


64

-8.2%

-10.3%

2.1%





122


126

-3.5%

-6.3%

2.8%


WW


95


101

-6.1%

-7.5%

1.4%





200


207

-3.3%

-5.0%

1.7%


CARDIOVASCULAR / METABOLISM / OTHER



















US


780


837

-6.9%

-6.9%

-





1,579


1,643

-3.9%

-3.9%

-


Intl


346


347

-0.3%

-8.4%

8.1%





674


701

-3.8%

-9.9%

6.1%


WW


1,126


1,184

-5.0%

-7.3%

2.3%





2,253


2,344

-3.9%

-5.7%

1.8%


XARELTO



















US


569


559

1.8%

1.8%

-





1,158


1,086

6.6%

6.6%

-


Intl


-


-

-

-

-





-


-

-

-

-


WW


569


559

1.8%

1.8%

-





1,158


1,086

6.6%

6.6%

-


INVOKANA / INVOKAMET



















US


96


132

-27.0%

-27.0%

-





183


249

-26.6%

-26.6%

-


Intl


64


47

33.8%

22.1%

11.7%





127


105

20.3%

12.2%

8.1%


WW


160


179

-10.9%

-14.0%

3.1%





310


354

-12.6%

-15.0%

2.4%


PROCRIT / EPREX



















US


59


70

-16.3%

-16.3%

-





121


146

-17.3%

-17.3%

-


Intl


69


66

3.7%

-4.5%

8.2%





133


145

-8.2%

-14.1%

5.9%


WW


127


136

-6.6%

-10.6%

4.0%





254


291

-12.8%

-15.7%

2.9%


OTHER



















US


57


78

-26.7%

-26.7%

-





117


163

-27.8%

-27.8%

-


Intl


214


234

-8.4%

-15.7%

7.3%





415


451

-8.1%

-13.7%

5.6%


WW


271


312

-13.0%

-18.4%

5.4%





532


614

-13.3%

-17.4%

4.1%


TOTAL PHARMACEUTICAL



















US


6,869


6,120

12.2%

12.2%

-





13,315


12,181

9.3%

9.3%

-


Intl


5,730


4,632

23.7%

15.4%

8.3%





11,483


9,705

18.3%

11.4%

6.9%


WW


$        12,599


10,752

17.2%

13.6%

3.6%





$        24,798


21,886

13.3%

10.3%

3.0%





















See footnotes at end of schedule




















REPORTED SALES vs. PRIOR PERIOD ($MM)





REPORTED SALES vs. PRIOR PERIOD ($MM)



SECOND QUARTER




SIX MONTHS







% Change








% Change


MEDICAL DEVICES SEGMENT (2)


2021


2020

Reported

Operational (1)

Currency





2021


2020

Reported

Operational (1)

Currency





















INTERVENTIONAL SOLUTIONS



















US


$             475


255

86.5%

86.5%

-





909


620

46.7%

46.7%

-


Intl


572


335

70.5%

59.8%

10.7%





1,086


697

55.7%

46.4%

9.3%


WW


1,046


590

77.4%

71.3%

6.1%





1,995


1,317

51.5%

46.5%

5.0%


ORTHOPAEDICS



















US 


1,323


869

52.3%

52.3%

-





2,572


2,119

21.4%

21.4%

-


Intl


904


583

55.1%

43.2%

11.9%





1,768


1,371

29.0%

20.2%

8.8%


WW


2,227


1,451

53.4%

48.6%

4.8%





4,340


3,489

24.4%

20.9%

3.5%


HIPS



















US


234


137

70.5%

70.5%

-





444


343

29.6%

29.6%

-


Intl


159


88

78.6%

64.3%

14.3%





305


220

38.3%

28.6%

9.7%


WW


392


226

73.7%

68.1%

5.6%





749


563

33.0%

29.2%

3.8%


KNEES



















US


210


108

94.3%

94.3%

-





395


322

22.7%

22.7%

-


Intl


140


66

*

95.1%

16.8%





272


196

39.2%

29.5%

9.7%


WW


350


174

*

94.6%

6.4%





667


517

28.9%

25.2%

3.7%


TRAUMA



















US


447


354

26.0%

26.0%

-





897


761

17.8%

17.8%

-


Intl


263


198

32.7%

22.7%

10.0%





545


445

22.5%

14.4%

8.1%


WW


710


553

28.4%

24.8%

3.6%





1,443


1,207

19.6%

16.5%

3.1%


SPINE, SPORTS & OTHER



















US


433


270

60.6%

60.6%

-





836


693

20.7%

20.7%

-


Intl


343


230

49.0%

37.9%

11.1%





646


510

26.7%

18.0%

8.7%


WW


776


499

55.3%

50.2%

5.1%





1,482


1,202

23.2%

19.6%

3.6%















































































REPORTED SALES vs. PRIOR PERIOD ($MM)




REPORTED SALES vs. PRIOR PERIOD ($MM)



SECOND QUARTER




SIX MONTHS







% Change








% Change




2021


2020

Reported

Operational (1)

Currency





2021


2020

Reported

Operational (1)

Currency


SURGERY



















US


1,035


490

*

*

-





1,933


1,334

44.9%

44.9%

-


Intl


1,487


1,060

40.2%

30.6%

9.6%





2,961


2,317

27.8%

20.4%

7.4%


WW


2,522


1,551

62.6%

56.0%

6.6%





4,894


3,651

34.0%

29.3%

4.7%


ADVANCED



















US


459


277

65.4%

65.4%

-





864


658

31.3%

31.3%

-


Intl


708


498

42.2%

32.5%

9.7%





1,421


1,065

33.4%

25.6%

7.8%


WW


1,168


775

50.5%

44.3%

6.2%





2,286


1,723

32.6%

27.8%

4.8%


GENERAL



















US


576


213

*

*

-





1,069


676

58.1%

58.1%

-


Intl


779


562

38.5%

28.9%

9.6%





1,540


1,252

23.0%

15.9%

7.1%


WW


1,354


775

74.7%

67.8%

6.9%





2,608


1,928

35.3%

30.7%

4.6%


VISION



















US


467


248

88.3%

88.3%

-





939


687

36.6%

36.6%

-


Intl


716


447

60.0%

53.7%

6.3%





1,389


1,075

29.2%

24.6%

4.6%


WW


1,183


695

70.1%

66.0%

4.1%





2,328


1,762

32.1%

29.3%

2.8%


CONTACT LENSES / OTHER



















US


352


203

73.3%

73.3%

-





723


549

31.6%

31.6%

-


Intl


517


352

47.0%

41.9%

5.1%





1,003


819

22.5%

18.5%

4.0%


WW


868


554

56.7%

53.4%

3.3%





1,725


1,368

26.1%

23.7%

2.4%


SURGICAL



















US


115


45

*

*

-





216


138

56.3%

56.3%

-


Intl


199


96

*

97.1%

10.6%





386


256

50.9%

44.4%

6.5%


WW


314


141

*

*

*





602


394

52.8%

48.6%

4.2%





















TOTAL MEDICAL DEVICES



















US


3,299


1,862

77.2%

77.2%

-





6,353


4,760

33.5%

33.5%

-


Intl


3,679


2,426

51.6%

41.9%

9.7%





7,204


5,460

31.9%

24.5%

7.4%


WW


$          6,978


4,288

62.7%

57.2%

5.5%





$        13,557


10,220

32.7%

28.7%

4.0%








































Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
 therefore, may not recalculate precisely.






















* Percentage greater than 100% or not meaningful
















(1) Operational growth excludes the effect of translational currency













(2) Unaudited



















(3) Certain prior year amounts have been reclassified to conform to current year product disclosures














(4) Reported as U.S. sales






































SOURCE Johnson & Johnson

Related Links

www.jnj.com

Adblock test (Why?)



"results" - Google News
July 21, 2021 at 05:25PM
https://ift.tt/3eDZGEe

Johnson & Johnson Reports Q2 2021 Results - PRNewswire
"results" - Google News
https://ift.tt/2SvRPxx
https://ift.tt/2Wp5bNh

Bagikan Berita Ini

0 Response to "Johnson & Johnson Reports Q2 2021 Results - PRNewswire"

Post a Comment


Powered by Blogger.